Mucormycosis During Second Wave of COVID-19 in India: Exploratory Analysis from Tertiary Care Centre of Uttar Pradesh

Background: In April and May 2021, India faced massive second wave of COVID-19 pandemic and then became the hotspots of mucormycosis across globe. Hence, we planned the first analysis of mucormycosis in Uttar Pradesh. Aim and Objectives: coThe objectives were to explore the epidemiology, vaccination status, clinical features, microbiological findings, treatment of mucormycosis and outcome. Material and Methods: This was an observational study of mucormycosis at tertiary care centre of Agra, Uttar Pradesh, India from 20 May 2021 to 15 July 2021. Results: 98 patients' data with mucormycosis was analyzed. Patients had median age of 55 years. COVID-19 infection was present in 69.4% of participants and diabetes mellitus was present as underlying co-morbid condition in more than 85% of patients. 91.8 % of cases were unvaccinated with steroid consumption in almost 60% of patients. R. arrhizus was among the most common agent while we found less commonly reported fungi like R.homothallicus, Apophysomyces, Cunninghamella. 41.8% of cases were successfully treated and 16.3% of cases expired. Conclusion: Diabetes mellitus was labeled as major predisposing factor and most patients were unvaccinated. Awareness about fungal infections, rigorous monitoring of chronic diseases, judicious use of drugs, early diagnosis and prompt treatment is decisive for better outcome.